TABLE 2.

Regional variation in susceptibility of BSI isolates of C. glabrata to azoles and echinocandins, 2001 to 2007

Region	Antifungal agent	No. tested	MIC (μg/ml)a			% of isolates that wereb:
			Range	50%	90%	S	R
West	Fluconazole	21	2->128	8	16	76	10
	Voriconazole	21	0.06-8	0.25	0.5	91	5
	Caspofungin	21	0.03-0.12	0.03	0.06	100	0c
Midwest	Fluconazole	368	1->128	8	64	61	12
	Voriconazole	368	0.015-8	0.25	2	90	7
	Anidulafungin	200	0.015-0.5	0.06	0.12	100	0c
	Caspofungin	345	0.015-4	0.03	0.06	99	0.3c
	Micafungin	178	0.007-0.12	0.015	0.015	100	0c
Northeast	Fluconazole	162	0.5->128	16	128	46	17
	Voriconazole	161	0.015->8	0.25	2	85	10
	Anidulafungin	78	0.015-0.25	0.06	0.12	100	0c
	Caspofungin	160	0.015-0.5	0.03	0.06	100	0c
	Micafungin	75	0.007-0.06	0.015	0.015	100	0c
South	Fluconazole	120	1->128	8	64	54	11
	Voriconazole	120	0.007-8	0.25	2	89	11
	Anidulafungin	45	0.03-0.25	0.06	0.12	100	0c
	Caspofungin	118	0.015-0.5	0.03	0.25	100	0c
	Micafungin	29	0.007-0.25	0.015	0.03	100	0c

^a50% and 90%, MICs encompassing 50% and 90% of isolates tested, respectively.

^bS, susceptible; R, resistant. Breakpoints are according to CLSI document M27-S3.

^cIsolates for which echinocandin MICs exceed 2 μg/ml are considered nonsusceptible.